Opiant Pharmaceuticals Inc
$
13.05
0 (0%)
| Volume: | 3,065 | Avg Vol (1m): | 19,597 |
| Market Cap $: | 52.14 Mil | Enterprise Value $: | 28.37 Mil |
| P/E (TTM): | 0.00 | P/B: | 3.07 |
| Earnings Power Value | -665.79 |
| Net Current Asset Value | 4.29 |
| Tangible Book | 4.29 |
| Projected FCF | 1.84 |
| Median P/S Value | 16.56 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 8.2/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | No Debt |
Cash-To-Debt range over the past 10 years
Min: 0.01, Med: 10000, Max: 10000
Current: 10000
| |
| Equity-to-Asset | 0.64 |
Equity-to-Asset range over the past 10 years
Min: -18.7, Med: 0.01, Max: 0.86
Current: 0.64
| |
| Interest Coverage | No Debt |
Interest Coverage range over the past 10 years
Min: 1773.25, Med: 10000, Max: 10000
Current: 10000
| |
| Piotroski F-Score | 6 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | -0.97 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -3.40 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 0%
WACC 3.99%
| ||
Profitability & Growth : 3/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -77.41 |
Operating Margin range over the past 10 years
Min: -445.1, Med: -114.87, Max: 38.45
Current: -77.41
| |
| Net Margin % | -76.71 |
Net Margin range over the past 10 years
Min: -454.06, Med: -115.27, Max: 35.68
Current: -76.71
| |
| ROE % | -92.91 |
ROE range over the past 10 years
Min: -200.02, Med: -200.02, Max: -92.91
Current: -92.91
| |
| ROA % | -59.87 |
ROA range over the past 10 years
Min: -20196.75, Med: -2432.84, Max: 103.72
Current: -59.87
| |
| ROC (Joel Greenblatt) % | -9314.54 |
ROC (Joel Greenblatt) range over the past 10 years
Min: -1412666.67, Med: -221085.71, Max: 141860
Current: -9314.54
| |
| 3-Year Total Revenue Growth Rate | 108.20 |
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 76.3
Current: 76.3
| |
| 3-Year Total EBITDA Growth Rate | -44.60 | N/A | |
| 3-Year EPS w/o NRI Growth Rate | -22.30 | N/A |
» OPNT's 30-Y Financials
Financials (Next Earnings Date: 2019-08-09)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:OPNT
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325412   SIC : 2834 |
| Compare | NAS:SNSS OSTO:ITECH XKRX:057880 TSXV:ARCH ROCO:6461 ROCO:4186 XTAE:BLRX NAS:ISEE TPE:4133 LSE:FARN NAS:EYEN ASX:MDC ASX:OCC OSTO:SENZA NGM:GTAB B XCNQ:PVOT OTCPK:ARTH AMEX:AMPE NAS:GNCA NAS:NLNK |
| Traded in other countries | 8OP.Germany |
| Address | 201 Santa Monica Boulevard, Suite 500, Santa Monica, CA, USA, 90401 |
| Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The pipeline product of the company candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| Forward PE Ratio | 29.67 | N/A | |
| PB Ratio | 3.07 |
PB Ratio range over the past 10 years
Min: 1.77, Med: 3.49, Max: 1651.3
Current: 3.07
| |
| PS Ratio | 2.45 |
PS Ratio range over the past 10 years
Min: 0.74, Med: 3.11, Max: 33.06
Current: 2.45
| |
| EV-to-EBIT | -2.08 |
EV-to-EBIT range over the past 10 years
Min: -3, Med: -1.4, Max: 34.5
Current: -2.08
| |
| EV-to-EBITDA | -2.08 |
EV-to-EBITDA range over the past 10 years
Min: -3, Med: -1.4, Max: 34.4
Current: -2.08
| |
| EV-to-Revenue | 1.63 |
EV-to-Revenue range over the past 10 years
Min: 0.1, Med: 2.6, Max: 31.2
Current: 1.63
| |
| Current Ratio | 2.77 |
Current Ratio range over the past 10 years
Min: 0.01, Med: 0.41, Max: 7.86
Current: 2.77
| |
| Quick Ratio | 2.77 |
Quick Ratio range over the past 10 years
Min: 0.01, Med: 0.41, Max: 7.86
Current: 2.77
| |
| Days Sales Outstanding | 40.31 |
Days Sales Outstanding range over the past 10 years
Min: 11.51, Med: 74.2, Max: 117.19
Current: 40.31
| |
| Days Payable | 35.55 |
Days Payable range over the past 10 years
Min: 27.18, Med: 27.18, Max: 35.55
Current: 35.55
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -17.50 |
3-Year Share Buyback Rate range over the past 10 years
Min: -38.6, Med: -6.4, Max: 22.1
Current: -17.5
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 3.04 |
Price-to-Tangible-Book range over the past 10 years
Min: 2.12, Med: 3.3, Max: 2742.14
Current: 3.04
| |
| Price-to-Projected-FCF | 7.09 |
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 2.74, Med: 5.97, Max: 13.14
Current: 7.09
| |
| Price-to-Median-PS-Value | 0.79 |
Price-to-Median-PS-Value range over the past 10 years
Min: 0.3, Med: 1.01, Max: 5.98
Current: 0.79
| |
| Earnings Yield (Joel Greenblatt) % | -48.27 |
Earnings Yield (Greenblatt) range over the past 10 years
Min: -7658.5, Med: -48.6, Max: 533.7
Current: -48.27
|
More Statistics
| Revenue (TTM) (Mil) $ | 17.71 |
| EPS (TTM) $ | -4.06 |
| Beta | 0.36 |
| Volatility % | 65.74 |
| 52-Week Range $ | 9.98 - 29.55 |
| Shares Outstanding (Mil) | 4 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 6 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | Y |